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Psoriasis is a chronic inflammatory disease affecting up to 2% of the
global population. While the pathogenesis of psoriasis is not fully
understood yet, an increasing body of evidence suggests a
genetic predisposition and an environmental component. The
most common manifestations are papulosquamous plaques sym-
metrically located on extensor surfaces of the joints. While most
psoriasis patients report that their skin manifestations have a nega-
tive impact on their quality of life, psoriasis is not just a skin disease.
Indeed, similarly to other systemic inflammatory diseases, inflam-
mation is widespread in psoriasis, and arthritis is found in up to
a quarter of patients and precedes the disease in 10% of the
patients.1 Importantly, life expectancy is reduced in psoriasis by
up to 4 years, which has been attributed to a higher incidence of
cardiovascular diseases.2
Ahlehoff et al. now report an association of psoriasis with
increased risk of atrial fibrillation and ischaemic stroke.3 The
authors analysed 36 765 patients with mild and 2793 patients
with severe psoriasis and compared these with . 4 million indivi-
duals of a nationwide Danish registry. Indeed, several important
pieces of information can be retrieved from this study. First, the
study is a further epidemiological milestone in delineating the asso-
ciated risk of not only severe but also mild psoriasis with vascular
disease. Secondly, the study demonstrates a considerably elevated
risk not only for cardiovascular disease per se but also for atrial fib-
rillation and ischaemic stroke, in particular. While confounding and
misclassification might be a concern in any registry-based study, the
authors provide further evidence that psoriasis is not just a skin
disease, but indeed a systemic disease. Notwithstanding that
patients with psoriasis have a high prevalence of cardiovascular
risk factors, such as smoking, dyslipidaemia, hypertension,
obesity, and insulin resistance, systemic inflammation beyond the
skin may provide an explanation for the increased cardiovascular
risk observed in psoriasis.1
Psoriasis shares striking similarities with other systemic inflam-
matory diseases, such as rheumatoid arthritis and atherosclerosis.
Intriguingly, the typical histological features of the psoriatic
plaque with dermal inflammation and leucocyte infiltration are
similar to those of the atherosclerotic plaque (Figure 1).4 In athero-
sclerosis, psoriasis, and rheumatoid arthritis, the activation of the
innate immune system starts an inflammatory cascade, particularly
involving T helper 1, T helper 17, regulatory T cells, and down-
stream expression of cytokines.5 Inflammation induced by psoriasis
also impacts on insulin resistance, both of which are important sur-
rogates for early, subclinical atherosclerosis and prognostic
markers for cardiovascular disease, and may alter the function of
endothelial cells, resulting in a propensity towards endothelial dys-
function and early structural changes of the arterial wall. Indeed,
several studies demonstrated impaired endothelial function and
increased intima-media thickness in patients with psoriasis.6
Does atrial fibrillation fit into the story of psoriasis being a sys-
temic inflammatory disease? Recent studies established chronic
inflammation as a risk factor for atrial fibrillation7 which is of par-
ticular clinical relevance as inflammation might contribute to the
prothrombotic state of atrial fibrillation and its clinical sequelae.8
Remarkably, Ahlehoff and colleagues also reported an increased
rate of venous thrombo-embolism in their cohort of psoriasis
patients.9
Since the study of Ahlehoff et al.3 adds to the increasing evi-
dence of increased cardiovascular risk in patients with chronic
inflammatory diseases, patients with psoriasis should be informed
by their treating physician that they may have an increased
chance of cardiovascular disease. This, however, begs two
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important questions with regard to potential therapeutical implica-
tions. First, should we be more aggressive in treating risk factors in
these patients, and secondly should we specifically target inflamma-
tion? Risk factors should be assessed, and lifestyle interventions
and pharmaceuticals prescribed as appropriate.10 Since LDL
levels are elevated and correlate with the severity of psoriasis,11
initiation of statins should be considered, and goals for LDL chol-
esterol levels should be based on cardiovascular risk assessment.
Close monitoring of liver function and creatine kinase are manda-
tory, especially in patients receiving immunosuppressive drugs, to
avoid liver toxicity and rhabdomyolysis. In addition to their well-
documented LDL-lowering effects, statins exert additional pleio-
tropic, anti-inflammatory effects, that may contribute to the
improvement of endothelial function demonstrated in patients
with atherosclerotic vascular disease as well as in patients with
rheumatoid arthritis, especially in those with high levels of systemic
inflammation.12 Intriguingly, cardiovascular treatment aimed at pre-
venting and treating atherosclerosis may also be beneficial in redu-
cing psoriasis disease severity, as statins reduced psoriatic
cutaneous plaque activity.13 While many patients with psoriasis
present with low HDL levels,11 there is currently no indication
for niacin and fibrates in patients with psoriasis, especially as
both of these drugs are associated with a worrisome higher rate
of side effects in patients with systemic inflammatory diseases.
ln patients with psoriasis and elevated blood pressure, lifestyle
changes should be implemented, and calcium antagonists, thiazide
diuretics, and angiotensin-converting enzyme inhibitors (ACEIs)
may represent the drugs of first choice. ACEIs also exert anti-
inflammatory and antioxidative effects, and are similarly effective
as statins in improving endothelial dysfunction in rheumatoid arth-
ritis.14 In contrast, beta-blockers should be prescribed with caution
since they are reported to be associated with the exacerbation of
psoriasis. While patients with systemic inflammatory disease have
not been included in previous cardiovascular outcome trials, ag-
gressive management of conventional cardiovascular risk factors
seems prudent in patients with systemic inflammatory disease
who show an increased cardiovascular risk similar to that of
diabetics.
The benefit of any specific anti-inflammatory therapy, however,
still remains to be established. In fact, anti-inflammatory drugs
might be double-edged, especially non-steroidal anti-inflammatory
drugs (NSAIDs) that are commonly used in psoriatic arthritis.
Their anti-inflammatory and analgesic effects notwithstanding,
NSAIDs and selective cyclo-oxygenase-2 (COX-2) inhibitors
increase blood pressure and cardiovascular risk.15 Their blood
pressure-raising effects must not be underestimated—notably an
effect is even observed with paracetamol (acetaminophen)16—as
hypertension has well known effects on the incidence of atrial fib-
rillation and stroke. As such, we are facing a dilemma when trying
specifically to target systemic inflammation. While antiinflamma-
tory drugs have the potential to provide benefit through targeting
inflammation, they may exert potent off-target effects. This is even
more problematic in severely symptomatic patients receiving
immunosuppressive drugs, since corticosteroids and ciclosporin
not only increase blood pressure, but also worsen dyslipidaemia,
all further enhancing cardio- and cerebrovascular risk. This true
equipoise is further documented by observational studies demon-
strating beneficial cardiovascular effects of low-dose
Figure 1 A much simplified schema for the development of atherosclerotic (above) and psoriatic (below) plaques. &National Psoriasis
Foundation.
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methotrexate.17 This sets the stage for cardiovascular outcome
trials with methothrexate currently under way, and will provide
the answer as to whether this anti-inflammatory and immunmodu-
latory drug will improve survival in high-risk cardiovascular
patients.
Novel biologics, such as tumour necrosis factor-a (TNF-a) inhi-
bitors have proven to be highly effective in the treatment of psor-
iasis and other inflammatory diseases. The first evidence of
whether potent anti-inflammatory treatment would not only alle-
viate symptoms but also impact on cardiovascular surrogates
came from studies demonstrating that TNF- a suppression
improved vascular function in patients with rheumatoid arthritis18
and may have a beneficial impact on carotid intima-media thickness
in psoriasis.19 Whether TNF- a blockade might beneficially impact
on cardiovascular morbidity and mortality in patients at increased
risk because of systemic inflammatory disease, however, still
remains to be determined.
Novel targeted biological agents for the treatment of psoriasis
are on the horizon, among them several monoclonal anti-
interleukin antibodies such as briakinumab, ustekinumab, and toci-
lizumab. Due to the shared immunological mechanisms between
psoriasis (and other inflammatory diseases) and atherosclerosis,
they may hold the potential for the treatment of both diseases,4
but randomized clinical trials addressing efficacy and safety are
yet to be performed.
Taken together, the study of Ahlehoff et al.3 adds to the increas-
ing body of evidence of an association between psoriasis and
cardio- and cerebrovascular diseases. Although inflammation in
these patients may not be limited to skin and joints, but indeed
be widespread throughout the vascular tree, there is an unmet
need for further research and outcome trials in this field. As a con-
sequence for clinicians, psoriasis patients, particularly those with
moderate or severe forms, should not only be treated for skin
lesions and arthritis but also rigorously screened for vascular risk
factors, especially as these patients are often young and could
therefore profit most when preventive strategies are implemented
early.10 In the future, large-scale randomized clinical trials are
needed to define whether patients with systemic inflammatory dis-
eases such as psoriasis will benefit from aggressive risk factor
control and/or anti-inflammatory treatment.
This would be of particular interest for our specialty, as the
benefit of a specific anti-inflammatory treatment has yet to be
established in the systemic inflammatory disease we care about
the most—atherosclerosis.
Funding
The Walter and Gertrud Siegenthaler Foundation (A.J.F.); the young
academics Support Committee of the University of Zurich (A.J.F.);
the Swiss foundation for medical–biological scholarships (SSMBS;
SNSF No. PASMP3_132551 to (A.J.F.); an institutional grant [Swiss
National Research Foundation (32000BO-105758) to F.R.].
Conflict of interest: none declared.
References
1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet
2007;370:263–271.
2. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myo-
cardial infarction in patients with psoriasis. JAMA 2006;296:1735–1741.
3. Ahlehoff O, Gislason GH, Jørgensen CH, Lindhardsen J, Charlot M, Olesen JB,
Abildstrøm SZ, Skov L, Torp-Pedersen C, Hansen PR. Psoriasis and risk of atrial
fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J
2012;33:2054–2064.
4. Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. A tale of two
plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and
atherosclerosis. Exp Dermatol 2011;20:544–549.
5. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the
biology of atherosclerosis. Nature 2011;473:317–325.
6. Balci DD, Balci A, Karazincir S, Ucar E, Iyigun U, Yalcin F, Seyfeli E, Inandi T,
Egilmez E. Increased carotid artery intima-media thickness and impaired endothe-
lial function in psoriasis. J Eur Acad Dermatol Venereol 2009;23:1–6.
7. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P,
Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK.
Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006–3010.
8. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and
C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am
Coll Cardiol 2004;43:2075–2082.
9. Ahlehoff O, Gislason GH, Lindhardsen J, Charlot MG, Jorgensen CH, Olesen JB,
Bretler DM, Skov L, Torp-Pedersen C, Hansen PR. Psoriasis carries an increased
risk of venous thromboembolism: a Danish nationwide cohort study. PLoS One
2011;6:e18125.
10. Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM,
Jarratt MT, Krueger JG, Ridker PM, Stone N, Roberts WC. AJC editor’s
consensus: psoriasis and coronary artery disease. Am J Cardiol 2008;102:
1631–1643.
11. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F.
Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for car-
diovascular disease. Clin Chim Acta 2001;303:33–39.
12. Hermann F, Forster A, Chenevard R, Enseleit F, Hurlimann D, Corti R, Spieker LE,
Frey D, Hermann M, Riesen W, Neidhart M, Michel BA, Hellermann JP, Gay RE,
Luscher TF, Gay S, Noll G, Ruschitzka F. Simvastatin improves endothelial func-
tion in patients with rheumatoid arthritis. J Am Coll Cardiol 2005;45:461–464.
13. Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: a pilot study.
J Am Acad Dermatol 2007;57:529–531.
14. Flammer AJ, Sudano I, Hermann F, Gay S, Forster A, Neidhart M, Kunzler P,
Enseleit F, Periat D, Hermann M, Nussberger J, Luscher TF, Corti R, Noll G,
Ruschitzka F. Angiotensin-converting enzyme inhibition improves vascular func-
tion in rheumatoid arthritis. Circulation 2008;117:2262–2269.
15. White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E,
Verburg KM. Risk of cardiovascular events in patients receiving celecoxib: a
meta-analysis of randomized clinical trials. Am J Cardiol 2007;99:91–98.
16. Sudano I, Flammer AJ, Periat D, Enseleit F, Hermann M, Wolfrum M, Hirt A,
Kaiser P, Hurlimann D, Neidhart M, Gay S, Holzmeister J, Nussberger J,
Mocharla P, Landmesser U, Haile SR, Corti R, Vanhoutte PM, Luscher TF,
Noll G, Ruschitzka F. Acetaminophen increases blood pressure in patients with
coronary artery disease. Circulation 2010;122:1789–1796.
17. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate
reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid
arthritis. J Am Acad Dermatol 2005;52:262–267.
18. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Bechir M,
Spieker LE, Neidhart M, Michel BA, Gay RE, Luscher TF, Gay S, Ruschitzka F. Anti-
tumor necrosis factor-alpha treatment improves endothelial function in patients
with rheumatoid arthritis. Circulation 2002;106:2184–2187.
19. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. Carotid intima-media
thickness in psoriatic arthritis: differences between tumor necrosis factor-alpha
blockers and traditional disease-modifying antirheumatic drugs. Arterioscler
Thromb Vasc Biol 2011;31:705–712.
Editorial 1991
